Andrew Kim, MD
Cardiology · Los Angeles, CANPI 1699858993
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 204 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations.
Across 204 payments — averaging $22.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$955
- Amgen$785
- Johnson & Johnson$761
- Novartis$650
- Boehringer Ingelheim$321
- Medtronic$159
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,57899%
- Education$561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $955 |
| Amgen | 33 | $785 |
| Johnson & Johnson | 32 | $761 |
| Novartis | 42 | $650 |
| Boehringer Ingelheim | 11 | $321 |
| Medtronic | 1 | $159 |
| Pfizer | 5 | $111 |
| Bayer | 4 | $105 |
| Edwards Lifesciences | 4 | $102 |
| Esperion Therapeutics, Inc. | 4 | $91 |
| Actelion Pharmaceuticals US, Inc. | 3 | $87 |
| E.r. Squibb & Sons, L.L.C. | 5 | $81 |
| Gilead | 4 | $75 |
| Stryker | 1 | $68 |
| Boston Scientific | 2 | $59 |
| Merck | 3 | $59 |
| Livanova USA, Inc. | 2 | $48 |
| Novo Nordisk | 2 | $39 |
| Lexicon Pharmaceuticals, Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAZOR X SYSTEM$159
How this compares
$4,634 in reported general payments places this provider in the 80th percentile of 156 cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 514 | $400,733 |
| EliquisApixaban | 429 | $325,644 |
| Repatha SureclickEvolocumab | 191 | $152,415 |
| EntrestoSacubitril/Valsartan | 176 | $148,733 |
| FarxigaDapagliflozin Propanediol | 92 | $77,390 |
| KerendiaFinerenone | 92 | $73,280 |
| JardianceEmpagliflozin | 98 | $67,577 |
| Praluent PenAlirocumab | 51 | $33,268 |
| OzempicSemaglutide | 24 | $32,608 |
| BrilintaTicagrelor | 46 | $24,970 |
| JanuviaSitagliptin Phosphate | 27 | $24,711 |
| Dexlansoprazole DrDexlansoprazole | 62 | $19,128 |
| Repatha SyringeEvolocumab | 24 | $14,797 |
| CreonLipase/Protease/Amylase | 15 | $13,257 |
| VascepaIcosapent Ethyl | 50 | $13,146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $761 | $400,733514 claims |
| PfizerEliquis | $111 | $325,644429 claims |
| NovartisEntresto | $650 | $148,733176 claims |
| AstraZenecaFarxiga, Brilinta | $955 | $102,361138 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $321 | $78,959121 claims |
| BayerKerendia | $105 | $73,28092 claims |
| MerckJanuvia, Janumet | $59 | $33,79739 claims |
| Novo NordiskOzempic | $39 | $32,60824 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $12 | $3,63511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 156 cardiology providers in California.
Other cardiology in Los Angeles
- Sanjay KaulLos Angeles$1.1M
- Jamshid MaddahiLos Angeles$59K
- Hooman MadyoonLos Angeles$24K
- Shawn ShahLos Angeles$3K
- Mark UrmanLos Angeles$1K
- Hiram PalmerLos Angeles$979
- Rene PackardLos Angeles$774
- Michael WongLos Angeles$510
- Norman LeporBeverly Hills$1.9M
- Ramtin AgahMountain View$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.